Evolus, Inc. Q4 2025 Earnings Call Summary
Evolus, Inc. Q4 2025 Earnings Call Summary – Moby It achieved 12% full-year revenue growth even though 2025 was only the third time in 25 years that US injectables volumes declined. He attributed Jeuveau’s 14% market share capture to a “beauty first” strategy that aligns with cash-based aesthetic practices rather than reimbursement models. A new…